Evaluasi Penggunaan Obat Antiemetik pada Penderita Kanker Payudara Pasca Kemoterapi

Evaluation of Antiemetic Drugs Use in Breast Cancer Patients After Chemotherapy

Authors

  • Dhea Amanda Sabilla Fauzi Laboratorium Penelitian dan Pengembangan Kefarmasian “Farmaka Tropis”, Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia
  • Hajrah Hajrah Laboratorium Penelitian dan Pengembangan Kefarmasian “Farmaka Tropis”, Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia
  • Yurika Sastyarina Laboratorium Penelitian dan Pengembangan Kefarmasian “Farmaka Tropis”, Fakultas Farmasi, Universitas Mulawarman, Samarinda, Indonesia

DOI:

https://doi.org/10.25026/mpc.v14i1.551

Keywords:

Breast Cancer, Nausea and Vomiting, Chemotherapy, Antiemetic

Abstract

Data from the Ministry of Health Republic Indonesia in 2018 showed 42,100 women had breast cancer. Chemotherapy is the main choice of treatment for treating cancer, but it has several side effects, such as nausea and vomiting. The aims of this research, to identify characteristics breast cancer patient, classification risk of chemotherapy induce of nausea and vomiting also appropriate use of antiemetic to prevent chemotherapy side effect. Observational research had been use for this study with retrospective data collection based on patient medical records in January-December 2020. The results showed that breast cancer patients were women with age range of 46-55 years with percentage 38.1% and 33.33% had Body Mass Index (BMI) Obesity I. Combination of Antibiotics and Taxanes is the most widely used by 71.45% and has the most common risk classification of moderate nausea and vomiting. The most widely used antiemetic is a combination of 5-Hydroxitryptamine-3, Antagonists Histamine 2, and Dexamethasone. 96.2% compliance with antiemetic use was achieved and 3.8% was not achieved.

References

Global Burden Cancer (GLOBOCAN). 2018. Tentang data kasus kanker payudara dan kanker serviks

Mardiana, A., & Kurniasari, L. 2021. Hubungan Pengetahuan Pemeriksaan Payudara Sendiri (SADARI) Dengan Kejadian Kanker Payudara Di Kalimantan Timur. Borneo Student Research (BSR), 2(2), 1052-1059.

Shinta, Nindya R., & Bakti, S. 2016. Terapi Mual Muntah Pasca Kemoterapi. Jurnal THT, 9(2), 74-83.

Azizah, N. 2017. Evaluasi Efektivitas Antiemetik pada Pasien Kanker Payudara Pasca Kemoterapi di RSUP Dr. Wahidin Sudirohusodo Makassar (Doctoral dissertation, Universitas Islam Negeri Alauddin Makassar).

Kurniati, Y. P., & Nafiah, I. 2019. Fenotipe Estrogen Reseptor Berdasarkan Usia dan Pekerjaan Pada Kanker Payudara Invasif. Proceeding of The URECOL, 709-715.

Irena, R. 2018. Hubungan Obesitas dengan Kejadian Kanker Payudara di RSUD Bangkinang. Prepotif: Jurnal Kesehatan Masyarakat, 2(1), 1-8.

Berger, M. J., Ettinger, D. S., Aston, J., Barbour, S., Bergsbaken, J., Bierman, P. J., ... & Hughes, M. 2017. NCCN guidelines insights: antiemesis, version 2.2017. Journal of the National Comprehensive Cancer Network, 15(7), 883-893.

Utaminingrum, W., Hakim, L., & Raharjo, B. (2013). Evaluasi Kepatuhan Dan Respon Mual Muntah Penggunaan Antiemetik Pada Pasien Kanker Payudara Yang Menjalani Kemoterapi Di Rsud Prof. Dr. Margono Soekarjo. Pharmacy: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia), 10(2).

Giovani, A., Hasmono, D., Surdijati, S., & Semedi, J. 2020. Studi Penggunaan Carboplatin untuk Penderita Kanker Payudara di RUMKITAL Dr. Ramelan Surabaya. Jurnal Farmasi Sains dan Terapan, 7(1), 27-35.

National Comprehensive Cancer Network. 2012. NCCN clinical practice guidelines in oncology antiemesis, Version 1.

Simbolon, P. D. H., Nafianti, S., Sianturi, P., Lubis, B., & Lelo, A. 2018. The addition of omeprazole to ondansetron for treating chemotherapy-induced nausea and vomiting in pediatric cancer patients. Paediatrica Indonesian, 58(1), 42-7.

Downloads

Published

2021-12-31

How to Cite

Fauzi, D. A. S., Hajrah, H., & Sastyarina, Y. (2021). Evaluasi Penggunaan Obat Antiemetik pada Penderita Kanker Payudara Pasca Kemoterapi: Evaluation of Antiemetic Drugs Use in Breast Cancer Patients After Chemotherapy. Proceeding of Mulawarman Pharmaceuticals Conferences, 14(1), 222–227. https://doi.org/10.25026/mpc.v14i1.551

Most read articles by the same author(s)

1 2 3 4 > >>